Clinical Trials · NCT03235050
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 834
- Start date
- Aug 2017
- Locations
- 119 sites, 8 countries
- Primary endpoint
- Change in HbA1c